Collagen News and Research

Latest Collagen News and Research

FDA accepts to review Fibrocell Science's azficel-T drug

Fibrocell Science, a biotechnology company focused on the development of autologous cell therapies for aesthetic, medical and scientific applications, announced today that the U.S. Food & Drug Administration has accepted for review the Company's complete response submission for azficel-T, proposed brand name laViv, for the treatment of moderate to severe nasolabial folds and wrinkles.

12 Jan 2011

Emerging Healthcare enters option agreement with OceanBASIS

Emerging Healthcare Solutions, Inc. announced today that it has entered into an option agreement with OceanBASIS, a German company specializing in stem-cell and marine-collagen technologies and products.

12 Jan 2011

Pro-Pharmaceuticals to begin DAVANAT Phase III development program following FDA approval

Pro-Pharmaceuticals, the leading developer of therapeutics that target Galectin receptors to treat cancer and fibrosis, today announced that on December 17, 2010, Company representatives met with officials from the U.S. Food & Drug Administration to present its Phase III clinical development program for DAVANAT.

11 Jan 2011

Findings of AM095 in various in vitro, in vivo models of fibrotic disease published in JPET

Amira Pharmaceuticals, Inc. announced today the publication of its findings in the Journal of Pharmacology and Experimental Therapeutics which describes the biologic effects and the characterization of AM095, a lysophosphatidic acid receptor 1 antagonist, in various in vitro and in vivo models of fibrotic disease.

6 Jan 2011

Increased amounts of MMP-1 enzyme may explain preeclampsia symptoms in pregnant women

Virginia Commonwealth University School of Medicine researchers have found that a significant increase of an enzyme in the blood vessels of pregnant women with preeclampsia may explain some of the symptoms associated with the condition, including hypertension, swelling and protein in the urine.

5 Jan 2011

Pro-Pharmaceuticals, Mount Sinai collaborate to evaluate anti-fibrotic effects of Galectin-targeting compounds

Pro-Pharmaceuticals, Inc., the leading developer of Galectin therapeutics to treat cancer and fibrosis, today announced it has entered into a new research collaboration with Mount Sinai School of Medicine to evaluate in pre-clinical models, the anti-fibrotic effects of several of the Company's novel, Galectin-targeting compounds.

21 Dec 2010

RXi's dermal anti-scarring candidate selected to advance into development

RXi Pharmaceuticals Corporation, a recognized leader in RNAi-based therapeutic discovery and development, today announced the selection of its first RNAi therapeutic product candidate to advance into development.

20 Dec 2010

BRIC researchers discover new protein that improves immune system

Researchers at BRIC, the University of Copenhagen, have discovered for the first time a protein normally found in the body that can act to prevent chronic tissue inflammation.

15 Dec 2010

CGEN-15001 administration shows dramatic therapeutic potential in CIA animal model

Compugen Ltd. announced today that administration of CGEN-15001 in an animal model of rheumatoid arthritis dramatically ameliorates the clinical symptoms of the disease.

15 Dec 2010

Fibrin microthreads support mesenchymal stem cell growth

A research team at Worcester Polytechnic Institute has demonstrated the feasibility of a novel technology that a surgeon could use to deliver stem cells to targeted areas of the body to repair diseased or damaged tissue, including cardiac muscle damaged by a heart attack. The technique involves bundling biopolymer microthreads into biological sutures and seeding the sutures with stem cells. The team has shown that the adult bone-marrow-derived stem cells will multiply while attached to the threads and retain their ability to differentiate and grow into other cell types.

10 Dec 2010

FDA grants approval to manufacture Collagenase SANTYL Ointment at DPT Laboratories' facility

Healthpoint today announced that the U.S. Food and Drug Administration has granted approval to manufacture commercial supplies of Collagenase SANTYL Ointment, a biologic enzymatic debriding agent, at DPT Laboratories' Center of Excellence for Sterile & Specialty Products facility in Lakewood, New Jersey.

10 Dec 2010

Systagenix launches new innovative website

Following the highly successful global launch of the new Corporate Identity, Systagenix has today unveiled its new innovative website - www.systagenix.com.

9 Dec 2010

DPT granted FDA approval to manufacture Collagenase SANTYL Ointment for wound care

DPT Laboratories, Ltd., a pharmaceutical contract development and manufacturing organization, announced today that it received FDA approval to manufacture commercial supplies of a leading sterile ointment for wound care at its Center of Excellence for Sterile & Specialty Products in Lakewood, N.J. Beginning this month, Healthpoint will ship commercial lots of Collagenase SANTYL® Ointment produced at DPT's Lakewood facility to its North American customers.

9 Dec 2010

Audax Medical licenses novel TBL technology to fix broken bones from Brown

Here's the vision: an elderly woman comes into the emergency room after a fall. She has broken her hip. The orthopaedic surgeon doesn't come with metal plates or screws or shiny titanium ball joints. Instead, she pulls out a syringe filled with a new kind of liquid that will solidify in seconds and injects into the break. Over time, new bone tissue will take its place, encouraged by natural growth factors embedded in the synthetic molecules of the material.

8 Dec 2010

First standard-of-care guidelines for children with congenital muscular dystrophy

In 2008, Eunice and Andrew Kim were facing a situation that would bewilder any parents: Two expert pediatric surgeons were giving opposing advice about treatment for their daughter.

8 Dec 2010

Journal of Hand Surgery publishes XIAFLEX CORD II phase III clinical trial

BioSpecifics Technologies Corp., a biopharmaceutical company developing first in class collagenase-based products, today announced that The Journal of Hand Surgery (JHS) has published in its December 2010 online edition pivotal CORD II phase III clinical trial of XIAFLEX (collagenase clostridium histolyticum), a novel, first-in-class biologic, conducted by BioSpecifics' strategic partner Auxilium Pharmaceuticals Inc., for the nonsurgical treatment of adult Dupuytren's contracture patients with a palpable cord.

8 Dec 2010

BioMimetic Therapeutics to assess safety, clinical utility of Augment Rotator Cuff Graft

BioMimetic Therapeutics, Inc. today announced it initiated enrollment in a pilot clinical trial to assess the safety and clinical utility of AugmentTM Rotator Cuff Graft for the repair of large rotator cuff tears. The randomized, controlled pilot trial is expected to include enrollment of up to 30 patients.

8 Dec 2010

Researchers synthesize wound-healing peptides

Newly-created bioactive peptides promote wound healing through the growth of new blood vessels and epithelial tissue, such as skin. These wound-healing peptides, synthesized by researchers at the Tufts Center for Innovations in Wound Healing Research, increased angiogenesis in vitro by 200 percent.

8 Dec 2010

Orthovita granted FDA marketing clearance for Vitoss Bioactive Foam-2X Bone Graft Substitute

Orthovita, Inc. , an orthobiologics and biosurgery company, announced today that it received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market Vitoss Bioactive Foam-2X Bone Graft Substitute for use as a non-structural bone void filler for use in the spine, pelvis and extremities. Orthovita expects to launch the newest addition to its bone graft substitute product line by late February or early March of 2011.

7 Dec 2010

OXIS introduces ErgoFlex for relief of joint pain

OXIS International, Inc. announces the market launch of ErgoFlex™, a unique new dietary supplement for the relief of joint pain. It is the first in a series of commercial products planned by OXIS. ErgoFlex is the only joint health complex containing the powerful antioxidant Ergothioneine (ERGO), and is specifically formulated to help the body fight the pain of joint inflammation and maintain optimal joint health.

7 Dec 2010

Collagen News and Research

Latest Collagen News and Research

FDA accepts to review Fibrocell Science's azficel-T drug

Emerging Healthcare enters option agreement with OceanBASIS

Pro-Pharmaceuticals to begin DAVANAT Phase III development program following FDA approval

Findings of AM095 in various in vitro, in vivo models of fibrotic disease published in JPET

Increased amounts of MMP-1 enzyme may explain preeclampsia symptoms in pregnant women

Pro-Pharmaceuticals, Mount Sinai collaborate to evaluate anti-fibrotic effects of Galectin-targeting compounds

RXi's dermal anti-scarring candidate selected to advance into development

BRIC researchers discover new protein that improves immune system

CGEN-15001 administration shows dramatic therapeutic potential in CIA animal model

Fibrin microthreads support mesenchymal stem cell growth

FDA grants approval to manufacture Collagenase SANTYL Ointment at DPT Laboratories' facility

Systagenix launches new innovative website

DPT granted FDA approval to manufacture Collagenase SANTYL Ointment for wound care

Audax Medical licenses novel TBL technology to fix broken bones from Brown

First standard-of-care guidelines for children with congenital muscular dystrophy

Journal of Hand Surgery publishes XIAFLEX CORD II phase III clinical trial

BioMimetic Therapeutics to assess safety, clinical utility of Augment Rotator Cuff Graft

Researchers synthesize wound-healing peptides

Orthovita granted FDA marketing clearance for Vitoss Bioactive Foam-2X Bone Graft Substitute

OXIS introduces ErgoFlex for relief of joint pain

Breathing New Life into Diagnostics: Plasmion's SICRIT Technology

Discover how SciY empowers scientists

Why use light scattering to analyze proteins and viral vectors?

Collagen News and Research

Latest Collagen News and Research

Breathing New Life into Diagnostics: Plasmion's SICRIT Technology

Discover how SciY empowers scientists

Why use light scattering to analyze proteins and viral vectors?

Newsletters you may be interested in